Osteoarthritis can turn simple activities such as walking, climbing stairs, or getting out of a chair into painful tasks.
Treatments injected directly into an affected joint can reduce symptoms, but their effects often fade because medicines do not remain inside the joint for very long.
Researchers at the University at Buffalo have developed an injectable material designed to keep treatment in place and release it slowly for weeks.
Osteoarthritis is the most common form of arthritis and a major cause of long-term pain and disability. It develops when the tissues that make a joint move smoothly begin to break down. The disease can affect the knees, hips, hands, spine, and other joints, and the risk generally rises with age.
Healthy joints contain cartilage that cushions the ends of bones and fluid that helps the joint move with little friction. In osteoarthritis, cartilage and other joint tissues change and may become damaged. Inflammation can also develop, contributing to pain, stiffness, swelling, and reduced movement.
Current treatments can help many patients manage symptoms, but they do not always stop the underlying disease. Pain medicines, physical therapy, exercise, weight management when appropriate, and injections are among the options doctors may use. In severe cases, joint replacement surgery may eventually be needed.
Some medicines are injected directly into the joint so that treatment is concentrated where it is needed. Corticosteroid injections can reduce inflammation and pain for a period of time, while substances designed to improve joint lubrication are also used in some patients. A major problem is that injected drugs can leave the joint relatively quickly.
This rapid removal makes it difficult to maintain a useful amount of medicine inside the joint for weeks or months. Repeated injections are inconvenient and can be uncomfortable, and increasing the amount of medicine may raise the risk of unwanted effects. The problem is even harder for drugs that do not dissolve well in water.
The University at Buffalo technology tries to overcome these problems with a hydrogel. A hydrogel is a water-rich material that can have properties somewhere between a liquid and a soft solid. The new formulation is designed to be injected as a liquid and then change after it reaches the warm environment inside the body.
At body temperature, the material quickly becomes a soft, slippery depot inside the joint. Instead of allowing the medicine to disperse and disappear rapidly, the depot holds it locally. The drug can then be released gradually over several weeks.
The platform combines a polymer-based gel with tiny drug-carrying particles. These nanocarriers can hold compounds that normally dissolve poorly in water, allowing more of the medicine to be placed inside the injectable material. The researchers designed the system using biocompatible materials with previous regulatory use in an effort to make future clinical development more practical.
Once inside the joint, medicine leaves the system gradually as it moves through the material and as the gel structure slowly relaxes. This controlled release could keep drug levels more stable near damaged joint tissues. At the same time, limiting treatment mainly to the joint could potentially reduce exposure elsewhere in the body.
The researchers have tested the platform with a compound that activates a protein called SIRT6. Scientists are studying SIRT6 because it is involved in processes linked to aging, inflammation, and cell health. These processes are relevant to osteoarthritis because the disease involves more than simple mechanical wear.
As joints age or become injured, some cells can enter an abnormal state in which they stop dividing but remain biologically active. These aging-like cells can release substances that promote inflammation and damage nearby tissue. Treatments aimed at such disease processes could potentially do more than temporarily block pain.
The hydrogel was therefore designed as a possible carrier for disease-modifying medicines. Rather than creating a single treatment for one drug, the researchers envision a platform that could carry different poorly soluble compounds. This flexibility could be useful as scientists develop new medicines targeting inflammation, cell aging, cartilage damage, or other causes of joint degeneration.
The gel may also provide a second benefit because its slippery physical properties could supplement lubrication inside the joint. In theory, the same injection could act both as a drug reservoir and as a material that helps surfaces move more smoothly. Whether this produces meaningful pain or mobility benefits in patients will need to be demonstrated in clinical studies.
Knee osteoarthritis is the main proposed use because it affects a very large number of people and injections into the knee are already common in medical practice. The developers also see possible applications in post-traumatic osteoarthritis, spinal disc degeneration, rotator cuff degeneration, and other conditions where a drug needs to remain concentrated in a particular area.
The technology comes from the University at Buffalo and is being developed as a sustained local drug-delivery platform for osteoarthritis. The information provided describes a translational technology rather than results from a completed large human clinical trial. Its promise therefore lies in what the delivery system may enable, not in proven patient outcomes at this stage.
The approach addresses a genuine problem in arthritis drug development. Even a medicine that works well in laboratory experiments may fail to help patients if it cannot remain in the joint at an effective concentration. A long-lasting injectable depot could potentially make some experimental drugs more practical while reducing how often injections are needed.
However, several questions remain before the technology could become routine treatment. Researchers will need to establish how long the gel safely remains in human joints, whether it causes irritation or immune reactions, how consistently it releases different medicines, and whether the drug levels are high enough to change disease without damaging surrounding tissues.
Most importantly, future studies must show that sustained drug delivery actually improves outcomes that matter to patients, such as pain, mobility, joint structure, and the need for surgery. A technically successful drug carrier is not automatically an effective osteoarthritis therapy. Different drugs placed inside the same platform could also have very different benefits and risks.
Overall, the hydrogel offers an appealing solution to one of the practical barriers in osteoarthritis treatment: keeping medicine inside a moving joint for long enough to work.
If future animal and human studies confirm its safety and effectiveness, the technology could turn a single injection into a longer-lasting treatment and open the door to medicines that are currently difficult to deliver.
If you care about health, please read studies about vitamin K deficiency linked to hip fractures in old people, and these vitamins could help reduce bone fracture risk.
For more health information, please see recent studies that Krill oil could improve muscle health in older people, and eating yogurt linked to lower frailty in older people.
Source: University at Buffalo.
